Recent Quotes View Full List My Watchlist Create Watchlist Indicators DJI Nasdaq Composite SPX Gold Crude Oil EL&P Market Index Markets Stocks ETFs Tools Overview News Currencies International Treasuries Articles published by Exelixis, Inc. < Previous 1 2 3 4 Next > Exelixis and Insilico Medicine Enter into Exclusive Global License Agreement for ISM3091, a Potentially Best-in-Class USP1 Inhibitor September 12, 2023 From Exelixis, Inc. Via Business Wire Tickers EXEL Exelixis Announces Positive Results from Phase 3 CABINET Pivotal Trial Evaluating Cabozantinib in Advanced Pancreatic and Extra-Pancreatic Neuroendocrine Tumors August 24, 2023 From Exelixis, Inc. Via Business Wire Tickers EXEL Exelixis Announces Appointment of Amy Peterson, M.D., as Executive Vice President, Product Development & Medical Affairs, and Chief Medical Officer August 23, 2023 From Exelixis, Inc. Via Business Wire Tickers EXEL Exelixis and Ipsen Announce Positive Results from Phase 3 CONTACT-02 Pivotal Trial Evaluating Cabozantinib in Combination with Atezolizumab in Metastatic Castration-Resistant Prostate Cancer August 21, 2023 From Exelixis, Inc. Via Business Wire Tickers EXEL Exelixis Announces Second Quarter 2023 Financial Results and Provides Corporate Update August 01, 2023 From Exelixis, Inc. Via Business Wire Tickers EXEL Exelixis, Inc. Announces Settlement of CABOMETYX® (cabozantinib) Patent Litigation with Teva Pharmaceuticals Development, Inc. and Teva Pharmaceuticals USA, Inc. July 23, 2023 From Exelixis, Inc. Via Business Wire Tickers EXEL Exelixis to Release Second Quarter 2023 Financial Results on Tuesday, August 1, 2023 July 18, 2023 From Exelixis, Inc. Via Business Wire Tickers EXEL Exelixis to Webcast Fireside Chats as Part of Investor Conferences in June May 30, 2023 From Exelixis, Inc. Via Business Wire Tickers EXEL Exelixis Announces First Quarter 2023 Financial Results and Provides Corporate Update May 09, 2023 From Exelixis, Inc. Via Business Wire Tickers EXEL Exelixis Announces Departure of Lance Willsey, M.D. From Board of Directors May 07, 2023 From Exelixis, Inc. Via Business Wire Tickers EXEL Exelixis to Present at the BofA Securities 2023 Healthcare Conference on May 10, 2023 May 03, 2023 From Exelixis, Inc. Via Business Wire Tickers EXEL Exelixis Files Definitive Proxy Statement and Mails Letter to Shareholders May 01, 2023 From Exelixis, Inc. Via Business Wire Tickers EXEL Exelixis to Release First Quarter 2023 Financial Results on Tuesday, May 9, 2023 April 25, 2023 From Exelixis, Inc. Via Business Wire Tickers EXEL Exelixis Advances Board Refreshment Plan April 13, 2023 From Exelixis, Inc. Via Business Wire Tickers EXEL Exelixis Reiterates Commitment to Shareholder Value Creation April 05, 2023 From Exelixis, Inc. Via Business Wire Tickers EXEL Exelixis Announces $550 Million Share Repurchase Program March 20, 2023 From Exelixis, Inc. Via Business Wire Tickers EXEL Exelixis to Webcast Fireside Chat at the 2023 Guggenheim Healthy Altitudes Summit March 13, 2023 From Exelixis, Inc. Via Business Wire Tickers EXEL Exelixis Provides Update on Phase 3 CONTACT-03 Trial Evaluating Cabozantinib in Combination with Atezolizumab in Patients with Previously Treated Advanced Kidney Cancer March 02, 2023 From Exelixis, Inc. Via Business Wire Tickers EXEL Exelixis to Webcast Fireside Chats as Part of Investor Conferences in March February 28, 2023 From Exelixis, Inc. Via Business Wire Tickers EXEL Exelixis and Sairopa Announce US FDA Clears Investigational New Drug Application for ADU-1805 in Patients with Advanced Solid Tumors February 13, 2023 From Exelixis, Inc. Via Business Wire Tickers EXEL Exelixis Announces Fourth Quarter and Full Year 2022 Financial Results and Provides Corporate Update February 07, 2023 From Exelixis, Inc. Via Business Wire Tickers EXEL Exelixis to Webcast Fireside Chats as Part of Investor Conferences in February February 02, 2023 From Exelixis, Inc. Via Business Wire Tickers EXEL Exelixis to Release Fourth Quarter and Full Year 2022 Financial Results on Tuesday, February 7, 2023 January 24, 2023 From Exelixis, Inc. Via Business Wire Tickers EXEL Exelixis Announces Update on Patent Litigation with MSN Laboratories January 19, 2023 From Exelixis, Inc. Via Business Wire Tickers EXEL Exelixis Announces Preliminary Fourth Quarter and Full Year 2022 Financial Results, Provides 2023 Financial Guidance, and Outlines Key Priorities and Milestones for 2023 January 08, 2023 From Exelixis, Inc. Via Business Wire Tickers EXEL Exelixis to Present at the 41st Annual J.P. Morgan Healthcare Conference on January 9, 2023 — Presentation to be webcast on www.exelixis.com — January 03, 2023 From Exelixis, Inc. Via Business Wire Tickers EXEL Exelixis Announces Initiation of the STELLAR-304 Phase 3 Pivotal Trial Evaluating Zanzalintinib in Patients with Advanced Non-Clear Cell Kidney Cancer December 22, 2022 From Exelixis, Inc. Via Business Wire Tickers EXEL Exelixis Provides Update on Phase 3 CONTACT-01 Trial Evaluating Cabozantinib in Combination with Atezolizumab in Patients with Metastatic Non-Small Cell Lung Cancer Previously Treated with Immunotherapy and Chemotherapy December 08, 2022 From Exelixis, Inc. Via Business Wire Tickers EXEL Exelixis Announces Initial Dose-Escalation Results from the First-in-Human Phase 1 Trial Evaluating XL102 in Patients with Advanced Solid Tumors at SABCS 2022 December 08, 2022 From Exelixis, Inc. Via Business Wire Tickers EXEL Exelixis to Present at the Virtual JMP Securities Hematology and Oncology Summit on December 7, 2022 November 30, 2022 From Exelixis, Inc. Via Business Wire Tickers EXEL < Previous 1 2 3 4 Next > Data & News supplied by www.cloudquote.io Stock quotes supplied by Barchart Quotes delayed at least 20 minutes. By accessing this page, you agree to the following Privacy Policy and Terms and Conditions.
